Sarcoglycanopathies: Clinical, Molecular and Genetic Characteristics, Epidemiology, Diagnostics and Treatment Options

1. 1.

   Meryon, E., On granular and fatty degeneration of the voluntary muscles, Med. Chir. Trans., 1852, vol. 35, pp. 73.1–84.1.

   CAS  PubMed  PubMed Central  Article  Google Scholar 

2. 2.

   Duchenne, G., Recherches sur la paralysie musculaire pseudohypertrophique en paralysie myosclerosique, Arch. Gen. Med., 1868, vol. 11, pp. 5–25.

   Google Scholar 

3. 3.

   Kloepfer, H.W. and Talley, C., Autosomal recessive inheritance of Duchenne-type muscular dystrophy, Ann. Hum. Genet., 1958, vol. 22, no. 2, pp. 138–143.

   CAS  PubMed  Article  Google Scholar 

4. 4.

   Koenig, M., Hoffman, E.P., Bertelson, C.J., et al., Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and reliminary genomic organization of the DMD gene in normal and affected individuals, Cell, 1987, vol. 50, no. 3, pp. 509–517.

   CAS  PubMed  Article  Google Scholar 

5. 5.

   Hoffman, E.P., Brown, R.H., Jr., and Kunkel, L.M., Dystrophin: the protein product of the Duchenne muscular dystrophy locus, Cell, 1987, vol. 51, no. 6, pp. 919–928.

   CAS  PubMed  Article  Google Scholar 

6. 6.

   Yoshida, M., Suzuki, A., Yamamoto, H., et al., Dissociation of the complex of dystrophin and its associated proteins into several unique groups by n-octyl beta-Dglucoside, Eur. J. Biochem., 1994, vol. 222, no. 3, pp. 1055–1061.

   CAS  PubMed  Article  Google Scholar 

7. 7.

   Ben Othmane, K., Ben Hamida, M., Pericak-Vance, M.A., et al., Linkage of Tunisian autosomal recessive Duchenne-like muscular dystrophy to the pericentromeric region of chromosome 13q, Nat. Genet., 1992, vol. 2, no. 4, pp. 315–317.

   PubMed  Article  Google Scholar 

8. 8.

   Bushby, K.M. and Beckmann, J.S., The limb—girdle muscular dystrophies—proposal for a new nomenclature, Neuromuscular Disord., 1995, vol. 5, no. 4, pp. 337–343.

   CAS  Article  Google Scholar 

9. 9.

   Richard, I., Broux, O., Allamand, V., et al., Mutations in the proteolytic enzyme calpain 3 cause limb—girdle muscular dystrophy type 2A, Cell, 1995, vol. 81, no. 1, pp. 27–40.

   CAS  PubMed  Article  Google Scholar 

10. 10.

    Bashir, R., Keers, S., Strachan, T., et al., Genetic and physical mapping at the limb—girdle muscular dystrophy locus (LGMD2B) on chromosome 2p, Genomics, 1996, vol. 33, no. 1, pp. 46–52.

    CAS  PubMed  Article  Google Scholar 

11. 11.

    Roberds, S.L., Anderson, R.D., Ibraghimov-Beskrovnaya, O., and Campbell, K.P., Primary structure and muscle-specific expression of the 50-kDa dystrophin-associated glycoprotein (adhalin), J. Biol. Chem., 1993, vol. 268, no. 32, pp. 23739–23742.

    CAS  PubMed  Google Scholar 

12. 12.

    Lim, L.E., Duclos, F., Broux, O., et al., Beta-sarcoglycan: characterization and role in limb—girdle muscular dystrophy linked to 4q12, Nat. Genet., 1995, vol. 11, no. 3, pp. 257–265.

    CAS  PubMed  Article  Google Scholar 

13. 13.

    Noguchi, S., McNally, E.M., Ben Othmane, K., et al., Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy, Science, 1995, vol. 270, no. 5237, pp. 819–822.

    CAS  PubMed  Article  Google Scholar 

14. 14.

    Passos-Bueno, M.R., Moreira, E.S., Vainzof, M., et al., Linkage analysis in autosomal recessive limb— girdle muscular dystrophy (AR LGMD) maps a sixth form to 5q33-34 (LGMD2F) and indicates that there is at least one more subtype of AR LGMD, Hum. Mol. Genet., 1996, vol. 5, no. 6, pp. 815–820.

    CAS  PubMed  Article  Google Scholar 

15. 15.

    Nigro, V., Piluso, G., Belsito, A., et al., Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein, Hum. Mol. Genet., 1996, vol. 5, no. 8, pp. 1179–1186.

    CAS  PubMed  Article  Google Scholar 

16. 16.

    Bonnemann, C.G., Modi, R., Noguchi, S., et al., Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex, Nat. Genet., 1995, vol. 11, no. 3, pp. 266–273.

    CAS  PubMed  Article  Google Scholar 

17. 17.

    Nigro, V., de Sa Moreira, E., Piluso, G., et al., Autosomal recessive limb—girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene, Nat. Genet., 1996, vol. 14, no. 2, pp. 195–198.

    CAS  PubMed  Article  Google Scholar 

18. 18.

    Roberds, S.L., Leturcq, F., Allamand, V., et al., Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy, Cell, 1994, vol. 78, no. 4, pp. 625–633.

    CAS  PubMed  Article  Google Scholar 

19. 19.

    Ettinger, A.J., Feng, G., and Sanes, J.R. Epsilon-sarcoglycan, a broadly expressed homologue of the gene mutated in limb—girdle muscular dystrophy 2D, J. Biol. Chem., 1997, vol. 272, no. 51, pp. 32534–32538.

    CAS  PubMed  Article  Google Scholar 

20. 20.

    Wheeler, M.T., Zarnegar, S., and McNally, E.M. Zeta-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy, Hum. Mol. Genet., 2002, vol. 11, no. 18, pp. 2147–2154.

    CAS  PubMed  Article  Google Scholar 

21. 21.

    Chen, J., Shi, W., Zhang, Y., et al., Identification of functional domains in sarcoglycans essential for their interaction and plasma membrane targeting, Exp. Cell Res., 2006, vol. 312, no. 9, pp. 1610–1625. doi 10.1016/j.yexcr.2006.01.024

    CAS  PubMed  Article  Google Scholar 

22. 22.

    Shiga, K., Yoshioka, H., Matsumiya, T., et al., Zetasarcoglycan is a functional homologue of gamma-sarcoglycan in the formation of the sarcoglycan complex, Exp. Cell Res., 2006, vol. 312, no. 11, pp. 2083–2092.

    CAS  PubMed  Article  Google Scholar 

23. 23.

    Chan, Y.M., Bonnemann, C.G., Lidov, H.G., and Kunkel, L.M. Molecular organization of sarcoglycan complex in mouse myotubes in culture, J. Cell Biol., 1998, vol. 143, no. 7, pp. 2033–2044.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

24. 24.

    Dickens, N.J., Beatson, S., and Ponting, C.P. Cadherin-like domains in alpha-dystroglycan, alpha/epsilon-sarcoglycan and yeast and bacterial proteins, Curr. Biol., 2002, vol. 12, no. 6, pp. R197–R199.

    CAS  PubMed  Article  Google Scholar 

25. 25.

    Betto, R., Senter, L., Ceoldo, S., et al., Ecto-ATPase activity of alpha-sarcoglycan (adhalin), J. Biol. Chem., 1999, vol. 274, no. 12, pp. 7907–7912.

    CAS  PubMed  Article  Google Scholar 

26. 26.

    Hack, A.A., Groh, M.E., and McNally, E.M. Sarcoglycans in muscular dystrophy, Microsc. Res. Tech., 2000, vol. 48, nos. 3–4, pp. 167–180. doi 10.1002/(sici)1097-0029(20000201/15)48:3/4<167::aidjemt5> 3.0.co;2-t

    CAS  PubMed  Article  Google Scholar 

27. 27.

    McNally, E.M., Duggan, D., Gorospe, J.R., et al., Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy, Hum. Mol. Genet., 1996, vol. 5, no. 11, pp. 1841–1847.

    CAS  PubMed  Article  Google Scholar 

28. 28.

    Hegde, R.S. and Kang, S.W., The concept of translocational regulation, J. Cell Biol., 2008, vol. 182, no. 2, pp. 225–232.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

29. 29.

    Hebert, D.N. and Molinari, M., In and out of the ER: protein folding, quality control, degradation, and related human diseases, Physiol. Rev., 2007, vol. 87, no. 4, pp. 1377–1408.

    CAS  PubMed  Google Scholar 

30. 30.

    Anelli, T. and Sitia, R., Protein quality control in the early secretory pathway, Embo J., 2008, vol. 27, no. 2, pp. 315–327.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

31. 31.

    Holt, K.H. and Campbell, K.P., Assembly of the sarcoglycan complex: insights for muscular dystrophy, J. Biol. Chem., 1998, vol. 273, no. 52, pp. 34667–34670.

    CAS  PubMed  Article  Google Scholar 

32. 32.

    Noguchi, S., Wakabayashi, E., Imamura, M., et al., Formation of sarcoglycan complex with differentiation in cultured myocytes, Eur. J. Biochem., 2000, vol. 267, no. 3, pp. 640–648.

    CAS  PubMed  Article  Google Scholar 

33. 33.

    Draviam, R.A., Shand, S.H., and Watkins, S.C. The beta-delta-core of sarcoglycan is essential for deposition at the plasma membrane, Muscle Nerve, 2006, vol. 34, no. 6, pp. 691–701.

    CAS  PubMed  Article  Google Scholar 

34. 34.

    Hack, A.A., Lam, M.Y., Cordier, L., et al., Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin–glycoprotein complex, J. Cell Sci., 2000, vol. 113. no. 14, pp. 2535–2544.

    CAS  PubMed  Google Scholar 

35. 35.

    Allikian, M.J. and McNally, E.M., Processing and assembly of the dystrophin glycoprotein complex, Traffic, 2007, vol. 8, no. 3, pp. 177–183.

    CAS  PubMed  Article  Google Scholar 

36. 36.

    Ozawa, E., Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era, Proc. Jpn. Acad., Ser. B, 2010, vol. 86, no. 8, pp. 798–821.

    CAS  Article  Google Scholar 

37. 37.

    Ervasti, J.M., Dystrophin, its interactions with other proteins, and implications for muscular dystrophy, Biochim. Biophys. Acta, 2007, vol. 2, pp. 108–117.

    Google Scholar 

38. 38.

    Petrof, B.J., Shrager, J.B., Stedman, H.H., et al., Dystrophin protects the sarcolemma from stresses developed during muscle contraction, Proc. Natl. Acad. Sci. U.S.A., 1993, vol. 90, no. 8, pp. 3710–3714.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

39. 39.

    Crosbie, R.H., Lim, L.E., Moore, S.A., et al., Molecular and genetic characterization of sarcospan: insights into sarcoglycan—sarcospan interactions, Hum. Mol. Genet., 2000, vol. 9, no. 13, pp. 2019–2027.

    CAS  PubMed  Article  Google Scholar 

40. 40.

    Brenman, J.E., Chao, D.S., Xia, H., et al., Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy, Cell, 1995, vol. 82, no. 5, pp. 743752.

    Article  Google Scholar 

41. 41.

    Yoshida, M., Hama, H., Ishikawa-Sakurai, M., et al., Biochemical evidence for association of dystrobrevin with the sarcoglycan–sarcospan complex as a basis for understanding sarcoglycanopathy, Hum. Mol. Genet., 2000, vol. 9, no. 7, pp. 1033–1040.

    CAS  PubMed  Article  Google Scholar 

42. 42.

    Davies, K.E. and Nowak, K.J., Molecular mechanisms of muscular dystrophies: old and new players, Nat. Rev. Mol. Cell Biol., 2006, vol. 7, no. 10, pp. 762773.

    Article  CAS  Google Scholar 

43. 43.

    Lapidos, K.A., Kakkar, R., and McNally, E.M. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma, Circ. Res., 2004, vol. 94, no. 8, pp. 1023–1031.

    CAS  PubMed  Article  Google Scholar 

44. 44.

    Thompson, T.G., Chan, Y.M., Hack, A.A., et al., Filamin 2 (FLN2): a muscle-specific sarcoglycan interacting protein, J. Cell Biol., 2000, vol. 148, no. 1, pp. 115–126.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

45. 45.

    Yoshida, T., Pan, Y., Hanada, H., et al., Bidirectional signaling between sarcoglycans and the integrin adhesion system in cultured L6 myocytes, J. Biol. Chem., 1998, vol. 273, no. 3, pp. 1583–1590.

    CAS  PubMed  Article  Google Scholar 

46. 46.

    Sandona, D., Danieli-Betto, D., Germinario, E., et al., The T-tubule membrane ATP-operated P2X4 receptor influences contractility of skeletal muscle, Faseb J., 2005, vol. 19, no. 9, pp. 1184–1186.

    CAS  PubMed  Article  Google Scholar 

47. 47.

    Li, D., Long, C., Yue, Y., and Duan, D. Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice, Hum. Mol. Genet., 2009, vol. 18, no. 7, pp. 1209–1220.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

48. 48.

    Zimprich, A., Grabowski, M., Asmus, F., et al., Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus—dystonia syndrome, Nat. Genet., 2001, vol. 29, no. 1, pp. 66–69.

    CAS  PubMed  Article  Google Scholar 

49. 49.

    Loo, T.W. and Clarke, D.M., Chemical and pharmacological chaperones as new therapeutic agents, Expert Rev. Mol. Med., 2007, vol. 9, no. 16, pp. 1–18.

    PubMed  Article  Google Scholar 

50. 50.

    Guglieri, M., Magri, F., D’Angelo, M.G., et al., Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients, Hum. Mutat., 2008, vol. 29, no. 2, pp. 258–266.

    CAS  PubMed  Article  Google Scholar 

51. 51.

    McNally, E.M., Yoshida, M., Mizuno, Y., et al., Human adhalin is alternatively spliced and the gene is located on chromosome 17q21, Proc. Natl. Acad. Sci. U.S.A., 1994, vol. 91, no. 21, pp. 9690–9694.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

52. 52.

    Trabelsi, M., Kavian, N., Daoud, F., et al., Revised spectrum of mutations in sarcoglycanopathies, Eur. J. Hum. Genet., 2008, vol. 16, no. 7, pp. 793–803. doi 10.1038/ejhg.2008.9

    CAS  PubMed  Article  Google Scholar 

53. 53.

    Moreira, E.S., Vainzof, M., Suzuki, O.T., et al., Genotype— phenotype correlations in 35 Brazilian families with sarcoglycanopathies including the description of three novel mutations, J. Med. Genet., 2003, vol. 40, no. 2, p. E12.

    Google Scholar 

54. 54.

    Hackman, P., Juvonen, V., Sarparanta, J., et al., Enrichment of the R77C alpha-sarcoglycan gene mutation in Finnish LGMD2D patients, Muscle Nerve, 2005, vol. 31, no. 2, pp. 199–204.

    CAS  PubMed  Article  Google Scholar 

55. 55.

    Carrie, A., Piccolo, F., Leturcq, F., et al., Mutational diversity and hot spots in the alpha-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D), J. Med. Genet., 1997, vol. 34, no. 6, pp. 470–475.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

56. 56.

    Tetreault, M., Srour, M., Allyson, J., et al., Founder mutation for alpha-sarcoglycan-LGMD2D in a Magdalen Islands Acadian cluster, Can. J. Neurol. Sci., 2011, vol. 38, no. 5, pp. 747–752.

    CAS  PubMed  Article  Google Scholar 

57. 57.

    Duggan, D.J., Gorospe, J.R., Fanin, M., et al., Mutations in the sarcoglycan genes in patients with myopathy, N. Engl. J. Med., 1997, vol. 336, no. 9, pp. 618624. doi 10.1056/nejm199702273360904

    Article  Google Scholar 

58. 58.

    Kawai, H., Akaike, M., Endo, T., et al., Adhalin gene mutations in patients with autosomal recessive childhood onset muscular dystrophy with adhalin deficiency, J. Clin. Invest., 1995, vol. 96, no. 3, pp. 1202–1207.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

59. 59.

    Bartoli, M., Gicquel, E., Barrault, L., et al., Mannosidase I inhibition rescues the human alpha-sarcoglycan R77C recurrent mutation, Hum. Mol. Genet., 2008, vol. 17, no. 9, pp. 1214–1221.

    CAS  PubMed  Article  Google Scholar 

60. 60.

    Tarnopolsky, M., Hoffman, E., Giri, M., et al., Alpha-sarcoglycanopathy presenting as exercise intol erance and rhabdomyolysis in two adults, Neuromuscul. Disord., 2015, vol. 25, no. 12, pp. 952–954.

    CAS  PubMed  Article  Google Scholar 

61. 61.

    Boito, C., Fanin, M., Siciliano, G., et al., Novel sarcoglycan gene mutations in a large cohort of Italian patients, J. Med. Genet., 2003, vol. 40, no. 5. e67. doi 10.1136/jmg.40.5.e67

    CAS  PubMed  PubMed Central  Article  Google Scholar 

62. 62.

    Eymard, B., Romero, N.B., Leturcq, F., et al., Primary adhalinopathy (alpha-sarcoglycanopathy): clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy, Neurology, 1997, vol. 48, no. 5, pp. 1227–1234.

    CAS  PubMed  Google Scholar 

63. 63.

    Piccolo, F., Roberds, S.L., Jeanpierre, M., et al., Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity, Nat. Genet., 1995, vol. 10, no. 2, pp. 243–245.

    CAS  PubMed  Article  Google Scholar 

64. 64.

    Bonnemann, C.G., Passos-Bueno, M.R., McNally, E.M., et al., Genomic screening for beta-sarcoglycan gene mutations: missense mutations may cause severe limb—girdle muscular dystrophy type 2E (LGMD 2E), Hum. Mol. Genet., 1996, vol. 5, no. 12, pp. 1953–1961.

    CAS  PubMed  Article  Google Scholar 

65. 65.

    Soheili, T., Gicquel, E., Poupiot, J., et al., Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum quality control is associated with minimal structural modifications, Hum. Mutat., 2012, vol. 33, no. 2, pp. 429–439. doi 10.1002/humu.21659

    CAS  PubMed  Article  Google Scholar 

66. 66.

    Duclos, F., Broux, O., Bourg, N., et al., Beta-sarcoglycan: genomic analysis and identification of a novel missense mutation in the LGMD2E Amish isolate, Neuromuscul. Disord., 1998, vol. 8, no. 1, pp. 30–38.

    CAS  PubMed  Article  Google Scholar 

67. 67.

    Klinge, L., Dekomien, G., Aboumousa, A., et al., Sarcoglycanopathies: can muscle immunoanalysis predict the genotype?, Neuromuscul. Disord., 2008, vol. 18, no. 12, pp. 934–941.

    PubMed  Article  Google Scholar 

68. 68.

    McNally, E.M., Passos-Bueno, M.R., Bonnemann, C.G., et al., Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation, Am. J. Hum. Genet., 1996, vol. 59, no. 5, pp. 1040–1047.

    CAS  PubMed  PubMed Central  Google Scholar 

69. 69.

    Piccolo, F., Jeanpierre, M., Leturcq, F., et al., A founder mutation in the gamma-sarcoglycan gene of gypsies possibly predating their migration out of India, Hum. Mol. Genet., 1996, vol. 5, no. 12, pp. 2019–2022.

    CAS  PubMed  Article  Google Scholar 

70. 70.

    Todorova, A., Ashikov, A., Beltcheva, O., et al., C283Y mutation and other C-terminal nucleotide changes in the gamma-sarcoglycan gene in the Bulgarian Gypsy population, Hum. Mutat., 1999, vol. 14, no. 1, pp. 40–44.

    CAS  PubMed  Article  Google Scholar 

71. 71.

    Morar, B., Gresham, D., Angelicheva, D., et al., Mutation History of the Roma/Gypsies, Am. J. Hum. Genet., 2004, vol. 75, no. 4, pp. 596–609.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

72. 72.

    Khadilkar, S.V., Singh, R.K., Hegde, M., et al., Spectrum of mutations in sarcoglycan genes in the Mumbai region of western India: high prevalence of 525delT, Neurol. India, 2009, vol. 57, no. 4, pp. 406–410. doi 10.4103/0028-3886.55603

    PubMed  Article  Google Scholar 

73. 73.

    El Kerch, F., Ratbi, I., Sbiti, A., et al., Carrier frequency of the c.525delT mutation in the SGCG gene and estimated prevalence of limb girdle muscular dystrophy type 2C among the Moroccan population, Genet. Test Mol. Biomarkers, 2014, vol. 18, no. 4, pp. 253–256. doi 10.1089/gtmb.2013.0326

    PubMed  PubMed Central  Article  CAS  Google Scholar 

74. 74.

    Jung, D., Duclos, F., Apostol, B., et al., Characterization of delta-sarcoglycan, a novel component of the oligomeric sarcoglycan complex involved in limb—girdle muscular dystrophy, J. Biol. Chem., 1996, vol. 271, no. 50, pp. 32321–32329.

    CAS  PubMed  Article  Google Scholar 

75. 75.

    Vainzof, M., Passos-Bueno, M.R., Canovas, M., et al., The sarcoglycan complex in the six autosomal recessive limb—girdle muscular dystrophies, Hum. Mol. Genet., 1996, vol. 5, no. 12, pp. 1963–1969.

    CAS  PubMed  Article  Google Scholar 

76. 76.

    Campbell, M.D., Witcher, M., Gopal, A., and Michele, D.E. Dilated cardiomyopathy mutations in delta-sarcoglycan exert a dominant-negative effect on cardiac myocyte mechanical stability, Am. J. Physiol.: Heart Circ. Physiol., 2016, vol. 310, no. 9, p. 11.

    Google Scholar 

77. 77.

    Karkkainen, S., Miettinen, R., Tuomainen, P., et al., A novel mutation, Arg71Thr, in the delta-sarcoglycan gene is associated with dilated cardiomyopathy, J. Mol. Med., 2003, vol. 81, no. 12, pp. 795–800.

    PubMed  Article  CAS  Google Scholar 

78. 78.

    Heydemann, A., Demonbreun, A., Hadhazy, M., et al., Nuclear sequestration of delta-sarcoglycan disrupts the nuclear localization of lamin A/C and emerin in cardiomyocytes, Hum. Mol. Genet., 2007, vol. 16, no. 4, pp. 355–363.

    CAS  PubMed  Article  Google Scholar 

79. 79.

    Bauer, R., Hudson, J., Muller, H.D., et al., Does delta-sarcoglycan-associated autosomal-dominant cardiomyopathy exist?, Eur. J. Hum. Genet., 2009, vol. 17, no. 9, pp. 1148–1153.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

80. 80.

    Chen, J., Jin, Y., Wang, H., et al., A haplotype of two novel polymorphisms in delta-sarcoglycan gene increases risk of dilated cardiomyopathy in mongoloid population, PLoS One, 2015, vol. 10, no. 12. e0145602. doi 10.1371/journal.pone.0145602

    Google Scholar 

81. 81.

    Schade van Westrum, S.M., Dekker, L.R., de Voogt, W.G., et al., Cardiac involvement in Dutch patients with sarcoglycanopathy: a cross-sectional cohort and follow-up study, Muscle Nerve, 2014, vol. 50, no. 6, pp. 909–913. doi 10.1002/mus.24233

    PubMed  Article  Google Scholar 

82. 82.

    Semplicini, C., Vissing, J., Dahlqvist, J.R., et al., Clinical and genetic spectrum in limb—girdle muscular dystrophy type 2E, Neurology, 2015, vol. 84, no. 17, pp. 1772–1781. doi 10.1212/wnl.0000000000001519

    CAS  PubMed  PubMed Central  Article  Google Scholar 

83. 83.

    Politano, L., Nigro, V., Passamano, L., et al., Evaluation of cardiac and respiratory involvement in sarcoglycanopathies, Neuromuscul. Disord., 2001, vol. 11, no. 2, pp. 178–185.

    CAS  PubMed  Article  Google Scholar 

84. 84.

    Pena, L., Kim, K., and Charrow, J. Episodic myoglobinuria in a primary gamma-sarcoglycanopathy, Neuromuscul. Disord., 2010, vol. 20, no. 5, pp. 337–339. doi 10.1016/j.nmd.2010.02.015

    PubMed  Article  Google Scholar 

85. 85.

    Ceravolo, F., Messina, S., Rodolico, C., et al., Myoglobinuria as first clinical sign of a primary alpha-sarcoglycanopathy, Eur. J. Pediatr., 2014, vol. 173, no. 2, pp. 239–242. doi 10.1007/s00431-013-2151-z

    CAS  PubMed  Article  Google Scholar 

86. 86.

    Walter, M.C., Dekomien, G., Schlotter-Weigel, B., et al., Respiratory insufficiency as a presenting symptom of LGMD2D in adulthood, Acta Myol., 2004, vol. 23, no. 1, pp. 1–5.

    CAS  PubMed  Google Scholar 

87. 87.

    Fayssoil, A., Drouet, T., Luis, D., et al., Acute ischemic stroke in gamma-sarcoglycanopathy, Presse Med., 2013, vol. 42, no. 4, part 1, pp. 484–486. doi 10.1016/j.lpm.2012.07.022

    PubMed  Article  Google Scholar 

88. 88.

    Norwood, F.L.M., Harling, C., Chinnery, P.F., et al., Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population, Brain, 2009, vol. 132, no. 11, pp. 3175–3186. doi 10.1093/brain/awp236

    PubMed  PubMed Central  Article  Google Scholar 

89. 89.

    Fanin, M., Duggan, D.J., Mostacciuolo, M.L., et al., Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations, J. Med. Genet., 1997, vol. 34, no. 12, pp. 973–977.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

90. 90.

    Moore, S.A., Shilling, C.J., Westra, S., et al., Limb— girdle muscular dystrophy in the United States, J. Neuropathol. Exp. Neurol., 2006, vol. 65, no. 10, pp. 995–1003.

    PubMed  Article  Google Scholar 

91. 91.

    Meena, A.K., Sreenivas, D., Sundaram, C., et al., Sarcoglycanopathies: a clinico-pathological study, Neurol. India, 2007, vol. 55, no. 2, pp. 117–121.

    CAS  PubMed  Article  Google Scholar 

92. 92.

    Gomez-Diaz, B., Rosas-Vargas, H., Roque-Ramirez, B., et al., Immunodetection analysis of muscular dystrophies in Mexico, Muscle Nerve, 2012, vol. 45, no. 3, pp. 338–345. doi 10.1002/mus.22314

    PubMed  Article  Google Scholar 

93. 93.

    Gouveia, T.L., Paim, J.F., Pavanello, R.C., et al., Sarcoglycanopathies: a multiplex molecular analysis for the most common mutations, Diagn. Mol. Pathol., 2006, vol. 15, no. 2, pp. 95–100.

    CAS  PubMed  Article  Google Scholar 

94. 94.

    Vainzof, M., Passos-Bueno, M.R., Pavanello, R.C., et al., Sarcoglycanopathies are responsible for 68% of severe autosomal recessive limb—girdle muscular dystrophy in the Brazilian population, J. Neurol. Sci., 1999, vol. 164, no. 1, pp. 44–49.

    CAS  PubMed  Article  Google Scholar 

95. 95.

    Ginjaar, H.B., van der Kooi, A.J., Ceelie, H., et al., Sarcoglycanopathies in Dutch patients with autosomal recessive limb girdle muscular dystrophy, J. Neurol., 2000, vol. 247, no. 7, pp. 524–529.

    CAS  PubMed  Article  Google Scholar 

96. 96.

    Stehlikova, K., Skalova, D., Zidkova, J., et al., Autosomal recessive limb—girdle muscular dystrophies in the Czech Republic, BMC Neurol., 2014, vol. 14, no. 154, pp. 014–0154.

    Google Scholar 

97. 97.

    Sveen, M.L., Schwartz, M., and Vissing, J. High prevalence and phenotype—genotype correlations of limb girdle muscular dystrophy type 2I in Denmark, Ann. Neurol., 2006, vol. 59, no. 5, pp. 808–815.

    CAS  PubMed  Article  Google Scholar 

98. 98.

    Cotta, A., Carvalho, E., da-Cunha-Junior, A.L., et al., Common recessive limb girdle muscular dystrophies differential diagnosis: why and how?, Arq. Neuropsiquiatr., 2014, vol. 72, no. 9, pp. 721–734.

    PubMed  Article  Google Scholar 

99. 99.

    Nalini, A., Gayathri, N., Thaha, F., et al., Sarcoglycanopathy: clinical and histochemical characteristics in 66 patients, Neurol. India, 2010, vol. 58, no. 5, pp. 691–696. doi 10.4103/0028-3886.72164

    CAS  PubMed  Article  Google Scholar 

100. 100.

     ten Dam, L., van der Kooi, A.J., van Wattingen, M., et al., Reliability and accuracy of skeletal muscle imaging in limb—girdle muscular dystrophies, Neurology, 2012, vol. 79, no. 16, pp. 1716–1723. doi 10.1212/WNL.0b013e31826e9b73

     PubMed  Article  Google Scholar 

101. 101.

     Wicklund, M.P. and Kissel, J.T., The limb—girdle muscular dystrophies, Neurol. Clin., 2014, vol. 32, no. 3, pp. 729–749.

     PubMed  Article  Google Scholar 

102. 102.

     Higuchi, I., Kawai, H., Umaki, Y., et al., Different manners of sarcoglycan expression in genetically proven alpha-sarcoglycan deficiency and gamma-sarcoglycan deficiency, Acta Neuropathol., 1998, vol. 96, no. 2, pp. 202–206.

     CAS  PubMed  Article  Google Scholar 

103. 103.

     Albuquerque, M.A., Abath-Neto, O., Maximino, J.R., et al., Clinical aspects of patients with sarcoglycanopathies under steroids therapy, Arq. Neuropsiquiatr., 2014, vol. 72, no. 10, pp. 768–772.

     PubMed  Article  Google Scholar 

104. 104.

     Angelini, C., Fanin, M., Menegazzo, E., et al., Homozygous alpha-sarcoglycan mutation in two siblings: one asymptomatic and one steroid-responsive mild limb—girdle muscular dystrophy patient, Muscle Nerve, 1998, vol. 21, no. 6, pp. 769–775.

     CAS  PubMed  Article  Google Scholar 

105. 105.

     Connolly, A.M., Pestronk, A., Mehta, S., and Al-Lozi, M. Primary alpha-sarcoglycan deficiency responsive to immunosuppression over three years, Muscle Nerve, 1998, vol. 21, no. 11, pp. 1549–1553.

     CAS  PubMed  Article  Google Scholar 

106. 106.

     Wong-Kisiel, L.C. and Kuntz, N.L., Two siblings with limb—girdle muscular dystrophy type 2E responsive to deflazacort, Neuromuscul. Disord., 2010, vol. 20, no. 2, pp. 122–124.

     PubMed  Article  Google Scholar 

107. 107.

     Fisher, I., Abraham, D., Bouri, K., et al., Prednisolone- induced changes in dystrophic skeletal muscle, Faseb J., 2005, vol. 19, no. 7, pp. 834–836.

     CAS  PubMed  Article  Google Scholar 

108. 108.

     Tamma, R., Annese, T., Capogrosso, R.F., et al., Effects of prednisolone on the dystrophin-associated proteins in the blood—brain barrier and skeletal muscle of dystrophic mdx mice, Lab. Invest., 2013, vol. 93, no. 5, pp. 592–610.

     CAS  PubMed  Article  Google Scholar 

109. 109.

     Mendell, J.R., Rodino-Klapac, L.R., Rosales, X.Q., et al., Sustained alpha-sarcoglycan gene expression after gene transfer in limb—girdle muscular dystrophy, type 2D, Ann. Neurol., 2010, vol. 68, no. 5, pp. 629638. doi 10.1002/ana.22251

     Google Scholar 

110. 110.

     Herson, S., Hentati, F., Rigolet, A., et al., A phase I trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C, Brain, 2012, vol. 135, part 2, pp. 483492. doi 10.1093/brain/awr342

     Article  Google Scholar 

111. 111.

     Vitiello, C., Faraso, S., Sorrentino, N.C., et al., Disease rescue and increased lifespan in a model of cardiomyopathy and muscular dystrophy by combined AAV treatments, PLoS One, 2009, vol. 4, no. 3, p. 31.

     Article  CAS  Google Scholar 

112. 112.

     Bianchini, E., Fanin, M., Mamchaoui, K., et al., Unveiling the degradative route of the V247M alphasarcoglycan mutant responsible for LGMD-2D, Hum. Mol. Genet., 2014, vol. 23, no. 14, pp. 3746–3758. doi 10.1093/hmg/ddu088

     CAS  PubMed  PubMed Central  Article  Google Scholar 

113. 113.

     Sandona, D. and Betto, R., Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects, Expert Rev. Mol. Med., 2009, vol. 11. e28. doi 10.1017/s1462399409001203

     PubMed  PubMed Central  Article  Google Scholar 

Download references